CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Botulinum Toxin Type A +1 moredrug
Likely dose
Botulinum Toxin Type A 2mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01177358
NCT01177358Phase 2Completed
CompareCT.gov

Botulinum Toxin A in the Healing of Surgical Wounds of the Neck: a Randomized, Prospective, Placebo-controlled Trial

Nova Scotia Health Authority·interventional·Posted Aug 9, 2010·Updated Aug 21, 2024

In Brief

A Phase 2 clinical trial evaluating Botulinum Toxin Type A and Normal Saline for Scar. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The investigators hypothesize that Botox A will reduce scarring and improve healing of surgical neck wounds.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScar
CountriesCanada
CollaboratorsAllergan

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2010
Enrollment StartMay 31, 2010
Primary CompletionMay 5, 2016
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 15.9 years ago

Interventions

Botulinum Toxin Type Adrug

A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy.

Normal Salinedrug

0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.